雷卢戈利克斯用于治疗前列腺癌:一篇综述
Ioannis Kyriazis1, Themistoklis Bellos2, Stamatios Katsimperis1
12nd Department of Urology, University of Athens, Sismanoglio General Hospital, Athens.
概括
口服GnRH抗剂Relugolix在没有爆发的情况下为晚期前列腺癌提供快速抑制. 与传统疗法相比,它显示出更高的疗效和心血管安全性.
科学领域:
- 在瘤学瘤学.
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 抗雄激素抑制疗法 (ADT) 是晚期前列腺癌的标准治疗方法.
- 传统的注射LHRH激动剂携带诸如丸激素爆发和心血管事件等风险.
- 瑞卢戈利克斯是一种口服的GnRH抗剂,旨在快速抑制没有爆发的.
研究的目的:
- 审查relugolix在晚期前列腺癌中的疗效,安全性和临床效用.
- 综合当前关于relugolix作为替代ADT选择的证据.
主要方法:
- 在2025年7月之前对PubMed和MEDLINE数据库进行非系统性审查.
- 搜索术语包括"relugolix"",ADT"",雄激素缺乏疗法"和"前列腺癌".
- 包括以英语出版的原始研究.
主要成果:
- 在HERO试验中,relugolix在持续割率和发病速度方面优于leuprolide.
- 瑞卢戈利克斯显示,主要心血管不良事件减少了54%.
- 观察到与德加利克斯相当的疗效,治疗后改善了丸激素的恢复.
结论:
- 雷卢戈力克斯是ADT的重大进步,提供一种口服,强效的选择.
- 它提供了快速的作用,有利的心血管安全概况,以及更好的恢复.
- 瑞卢戈力克斯是治疗晚期前列腺癌的宝贵选择,尤其是患有心血管疾病的患者.
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Drugs for Treatment of Constipation-Predominant IBS
686
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
686
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
447
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
447
Drugs for Treatment of Ulcerative Colitis in IBD
439
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
439
Drugs for Treatment of Diarrhea-Predominant IBS
612
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
612


